Immune landscape of early-onset cancers: Clinical significance and novel intervention targets
EXCLI Journal · 2026-11-05 · 25 · 1674-1693
DOI: 10.17179/excli2026-9733 ↗Abstract
Early-onset cancers (diagnosed before age 45) are rising globally and demonstrate distinct biological characteristics compared to late-onset malignancies. While epidemiological trends are well-documented, the immune mechanisms for different disease trajectories in young adults remain poorly characterized. This review synthesizes and compares immune landscapes across early-onset cancers, identifying common immunological features and their interactions with non-immune factors including host genetics, tumor-intrinsic alterations, and microbiome dysbiosis. Young patients frequently exhibit preserved or elevated immune cell infiltration alongside functionally suppressed adaptive responses with TLS presence but without concurrent functional enhancement, impaired antigen presentation, and enhanced immunosuppressive cell populations. This creates a functionally “cold” tumor microenvironment in most cancer types that is fundamentally different from late-onset tumors. Concurrently, systemic immunity is characterized by altered T-cell subsets, metabolic shifts, and elevated inflammatory cytokines, though the existing literature remains limited and fragmented, representing a critical knowledge gap hindering peripheral biomarker development. Importantly, immune profiles are often driven more by molecular subtype, sex, and hormonal context than by age alone, underscoring the necessity for multi-level stratification. Notably, this immunosuppressive profile does not consistently translate to inferior responses to immune checkpoint inhibitor therapy, though young patients experience higher toxicity rates. Future studies must prioritize comprehensive systemic immune profiling, multi-omic signature development, and mechanistic investigations into functional immunosuppression despite immune infiltration. Prospective biomarker-guided trials with age- and molecular-stratified designs are essential to develop precision immunotherapies tailored to the unique immunobiology of young adults, ultimately improving outcomes in this increasingly affected population.
EUVIMED